Search results
Results from the WOW.Com Content Network
An anti-CEA antibody is an antibody against CEA. Such antibodies to CEA are commonly used in immunohistochemistry to identify cells expressing the glycoprotein in tissue samples. In adults, CEA is primarily expressed in cells of tumors (some malignant, some benign) [ 19 ] but they are particularly associated with the adenocarcinomas , such as ...
Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) (CEACAM1) also known as CD66a (Cluster of Differentiation 66a), is a human glycoprotein, and a member of the carcinoembryonic antigen (CEA) gene family.
n/a Ensembl ENSG00000105388 n/a UniProt P06731 n/a RefSeq (mRNA) NM_001291484 NM_001308398 NM_004363 n/a RefSeq (protein) NP_001278413 NP_001295327 NP_004354 n/a Location (UCSC) Chr 19: 41.71 – 41.73 Mb n/a PubMed search n/a Wikidata View/Edit Human Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (C luster of D ifferentiation 66e), is a member of the ...
The AE1 glycoprotein is expressed only in red blood cells and, in a shortened form, in some cells in the kidney. The Diego a antigen is fairly common in Indigenous peoples of the Americas (in both North and South America) and East Asians , but very rare or absent in most other populations, supporting the theory that the two groups share common ...
Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary, [1] [2] [3] breast, colon, [4] lung, and pancreatic cancers. [ 5 ] [ 6 ] It is a mucin -like molecule with a molar mass of over 1000 kDa .
Guidelines from the American Society of Clinical Oncology discourage the use of CA19-9 as a screening test for cancer, particularly pancreatic cancer.The reason is that the test may be falsely normal (false negative) in many cases or abnormally elevated in people who have no cancer (false positive) in others.
Although antibodies exhibit nanomolar affinities toward protein antigens, the specificity against glycans is very limited. [8] In fact, available antibodies may bind only <4% of the 7000 mammalian glycan antigens; moreover, most of those antibodies have low affinity and exhibit cross-reactivity. [9] [7]
By providing information on mechanism of action, epitope mapping is a critical component in therapeutic monoclonal antibody (mAb) development. Epitope mapping can reveal how a mAb exerts its functional effects - for instance, by blocking the binding of a ligand or by trapping a protein in a non-functional state.